Intermittent Claudication: A Review

Pentoxifylline for intermittent claudication. A critical review.

Pentoxifylline was first introduced in Germany twenty years ago. Today it is the best researched oral drug for intermittent claudication. A total of seventeen placebo-controlled trials could be retrieved from the world literature. The majority of these studies show that pentoxifylline will prolong the walking distance in a statistically significant way. Even though these trials are conducted wi...

Intermittent claudication

Peripheral arterial disease is a common health problem that globally affects over 200 million individuals, and intermittent claudication (IC) is the most common symptomatic presentation. The leg symptoms in IC are provoked by walking exercise and can be alleviated by medical intervention, exercise training and invasive vascular interventions (revascularization). The quality of evidence for inva...

Intermittent claudication; a clinical study.

Patients with Intermittent Claudication

Increased blood viscosity has been shown to be an important factor in reducing blood flow in a review and analysis of the history, clinical findings, and haemodynamic, rheological, radiological, and biochemical measurements in 126 patients with intermittent claudication. In some patients increased viscosity seemed to be the determining cause of claudication. A raised plasma fibrinogen was the m...

Pentoxifylline for intermittent claudication.

BACKGROUND Intermittent claudication (IC) is a symptom of peripheral arterial disease (PAD) and is associated with high morbidity and mortality. Pentoxifylline, one of many drugs used to treat IC, acts by decreasing blood viscosity, improving erythrocyte flexibility and promoting microcirculatory flow and tissue oxygen concentration. Many studies have evaluated the efficacy of pentoxifylline in...